Fig 6. Schematic model showing phenotypic progression of PCa from primary adenocarcinoma (presented by PLum-AD cells) to advanced CRPC (presented by PLum-AI cells) and the effects of SB203580 and IL-6 on this progression.

PLum-AD cells which demonstrate an epithelial phenotype undergo EMT following the exposure to IL-6, whereas Plum-AI cells which exhibit a mesenchymal phenotype undergo MErT upon treatment with the p38 MAPK inhibitor SB203580.